Quick Answer
SANGAMO THERAPEUTICS, INC reported Research And Development Expense of $112.67 million for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed an increase of +1.0% in Research And Development Expense from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $7.15 million | Q3 2010: $8.77 million | Q1 2011: $8.26 million | Q2 2011: $8.12 million | Q3 2011: $7.84 million | Q1 2012: $7.28 million | Q2 2012: $7.57 million | Q3 2012: $7.57 million | Q1 2013: $8.22 million | Q2 2013: $9.28 million | Q3 2013: $8.70 million | Q1 2014: $12.08 million | Q2 2014: $13.46 million | Q3 2014: $16.34 million | Q1 2015: $14.98 million | Q2 2015: $15.62 million | Q3 2015: $16.69 million | Q1 2016: $15.27 million | Q2 2016: $19.45 million | Q3 2016: $17.01 million | Q1 2017: $12.94 million | Q2 2017: $14.98 million | Q3 2017: $18.43 million | Q1 2018: $23.55 million | Q2 2018: $29.26 million | Q3 2018: $28.81 million | Q1 2019: $34.85 million | Q2 2019: $36.46 million | Q3 2019: $36.29 million | Q1 2020: $41.48 million | Q2 2020: $41.52 million | Q3 2020: $45.29 million | Q1 2021: $56.43 million | Q2 2021: $60.09 million | Q3 2021: $62.50 million | Q1 2022: $58.58 million | Q2 2022: $60.02 million | Q3 2022: $65.12 million | Q1 2023: $63.22 million | Q2 2023: $63.05 million | Q3 2023: $57.09 million | Q1 2024: $35.89 million | Q2 2024: $24.22 million | Q3 2024: $27.73 million | Q1 2025: $26.01 million | Q2 2025: $27.08 million | Q3 2025: $28.14 million.
- Over the full 17 years of available data (2009 to 2025), SANGAMO THERAPEUTICS, INC's Research And Development Expense has grown by 288.7%.
- Historical annual values: Fiscal year 2025: $112.67 million | Fiscal year 2024: $111.52 million | Fiscal year 2023: $234.06 million | Fiscal year 2022: $249.90 million | Fiscal year 2021: $230.82 million | Fiscal year 2020: $180.65 million | Fiscal year 2019: $145.92 million | Fiscal year 2018: $114.87 million | Fiscal year 2017: $65.73 million | Fiscal year 2016: $65.62 million | Fiscal year 2015: $67.20 million | Fiscal year 2014: $56.97 million | Fiscal year 2013: $37.04 million | Fiscal year 2012: $31.71 million | Fiscal year 2011: $32.10 million | Fiscal year 2010: $33.15 million | Fiscal year 2009: $28.98 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: